Our objective
Our mission is to investigate the role of immune cells in cardiovascular diseases such as atherosclerosis, peripheral artery disease (PAD), and heart failure.
We aim to design and test novel immunotherapies to modulate inflammation, enhance vascular repair, and prevent adverse cardiac events.
Our impact
Our research aims to advance the understanding of immune cell interactions in atherosclerosis, peripheral artery disease (PAD), and heart failure, leading to innovative strategies that modulate immune responses, enhance vascular repair, and prevent adverse cardiac events.
Selected publications
Cartland SP et al. The generation of stable microvessels in ischemia is mediated by endothelial cell derived TRAIL. Sci Adv. 2024 Oct 4;10(40):eadn8760.
Cartland SP, et al. Sex, Endothelial Cell Functions, and Peripheral Artery Disease. Int J Mol Sci. 2023 Dec 13;24(24):17439.
Kelland E, et al. The Prognostic, Diagnostic, and Therapeutic Potential of TRAIL Signalling in Cardiovascular Diseases. Int J Mol Sci. 2023 Apr 4;24(7):6725.
Cartland SP, et al. "Western Diet" promotes symptoms of hepatic steatosis in spontaneously hypertensive rats. Int J Exp Pathol. 2020 Oct;101(5):152-161.
Cartland SP, et al. Vascular transcriptome landscape of Trail-/- mice: Implications and therapeutic strategies for diabetic vascular disease. FASEB J. 2020 Jul;34(7):9547-9562.
Cartland SP et al. TRAIL-Expressing Monocyte/Macrophages Are Critical for Reducing Inflammation and Atherosclerosis. iScience. 2019 Feb 22;12:41-52.